CNBC's 'Squawk Box' breaks down Johnson & Johnson's latest third-quarter earnings report.
said it sold $502 million of its Covid-19 vaccine in the third quarter, in its earnings report Tuesday that beat Wall Street's profit expectations.
Here's how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:Revenue: $23.34 billion vs $23.72 billion expected. J&J increased its full-year earnings guidance to between $9.77 per share and $9.82 per share, from its previous estimates of $9.60 to $9.70 per share. It expects sales to range from $94.1 billion to $94.6 billion, up from previous guidance of $93.8 billion to $94.6 billion.
At the same time, the company maintained its Covid vaccine sales outlook for the year at $2.5 billion.J&J's report came under a shadow of criticism about how it handled the opioid crisis and the development of a comparatively less-effective Covid vaccine under outgoing CEO Alex Gorsky. In a press release, Gorsky said the financial results "demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health."Correction: This story was updated to reflect that J&J missed revenue estimates.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Powell was being treated for multiple myeloma, fully vaccinated for Covid before deathBefore his death, former Secretary of State Colin Powell was being treated for multiple myeloma at Walter Reed National Medical Center and he was fully vaccinated from Covid-19. NBC News' Andrea Mitchell remembers Colin Powell as an American leader and a friend.
Lire la suite »
Colin Powell dies from Covid complicationsColin Powell, a four-star general who became America's first Black secretary of State, has died. He was 84.
Lire la suite »
Op-Ed: Refrigeration alone can't solve the 'last mile' problem for COVID-19 vaccinesHumanitarian aid groups have experience countering myths and misinformation to overcome vaccine hesitancy in low-income countries.
Lire la suite »
Why COVID-19 booster shots weren't tweaked to better match Delta variantMore COVID-19 booster shots may be on the way — but when it’s your turn, you’ll get an extra dose of the original vaccine formulation, not one updated to better match the extra-contagious Delta variant.
Lire la suite »